









Markets
/
Stocks
/
nasdaq-rfl
/

Rafael Holdings Inc

RFL

1.220USD

+0.040+3.39%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

63.92MMarket Cap

LossP/E TTM



Rafael Holdings Inc

1.220

+0.040+3.39%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rafael Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Rafael Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 119 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rafael Holdings Inc's Score

Industry at a Glance

Industry Ranking

119 / 159

Overall Ranking

399 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Rafael Holdings Inc Highlights

StrengthsRisks

Rafael Holdings, Inc. is a biotechnology company. The Company holds interests in clinical and early-stage pharmaceutical companies, including a 100% interest in Cyclo Therapeutics, LLC, a biotechnology company focusing on developing its lead clinical candidate, Trappsol Cyclo, which is being evaluated in clinical trials, including an ongoing Phase III trial for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. It also holds an interest in LipoMedix Pharmaceuticals Ltd., a clinical-stage pharmaceutical company; Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, and an interest in Cornerstone Pharmaceuticals, Inc., a cancer metabolism-based therapeutics company. It holds an interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 228.67% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 917.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 917.00K.

Fairly Valued

The company’s latest PE is -1.45, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.73M shares, decreasing 18.90% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 76.43K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.03.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Rafael Holdings Inc is 7.14, ranking 129 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 240.00K, representing a year-over-year increase of 87.50%, while its net profit experienced a year-over-year increase of 8.99%.

Score

Industry at a Glance

Previous score

7.14

Change



Financials

9.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.10

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.75

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.27

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.30

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Rafael Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Rafael Holdings Inc is 7.95, ranking 38 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -1.45, which is -1526.92% below the recent high of 20.66 and -2002.74% above the recent low of -30.44.

Score

Industry at a Glance

Previous score

7.95

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 119/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Rafael Holdings Inc. The Pharmaceuticals industry's average is 7.85.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Rafael Holdings Inc is 6.52, ranking 124 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.31 and the support level at 1.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.20

Change

0.32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.003

Neutral

RSI(14)

50.920

Neutral

STOCH(KDJ)(9,3,3)

48.344

Buy

ATR(14)

0.064

High Vlolatility

CCI(14)

100.522

Buy

Williams %R

43.503

Buy

TRIX(12,20)

-0.235

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.186

Buy

MA10

1.189

Buy

MA20

1.212

Buy

MA50

1.243

Sell

MA100

1.292

Sell

MA200

1.485

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Rafael Holdings Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 7.31%, representing a quarter-over-quarter increase of 2.27%. The largest institutional shareholder is The Vanguard, holding a total of 1.49M shares, representing 2.93% of shares outstanding, with 8.74% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Jonas (Howard S)

14.00M

-0.07%

i9 PLUS, L.L.C.

3.62M

The Vanguard Group, Inc.

Star Investors

1.39M

+10.54%

Conkling (William)

490.77K

-13.05%

IEQ Capital LLC

423.09K

+88.85%

Geode Capital Management, L.L.C.

355.45K

-21.21%

Fine (Nathan Scott)

335.35K

BlackRock Institutional Trust Company, N.A.

318.43K

-16.94%

Polinsky (David)

258.68K

-0.75%

Dimensional Fund Advisors, L.P.

298.23K

-11.54%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Rafael Holdings Inc is 3.30, ranking 105 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.60. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.